|
Workshop
[In-Person] Preclinical Development and IND Filing for Antibody-Based Therapeutics: Nuts, Bolts and Best Practices
Speakers:
Laurence Fayadat-Dilman (Merck and Co), Keegan Cooke (Amgen), Jay Tibbitts (Surrozen), Robert Caldwell (AbbVie), Lilia Koriazova (Erasca), Sara Glickstein Bar-Zeev (Genentech); Key Kang (Genentech), Arianne L. Motter (FDA)
Organizers:
Ayse Meric Ovacik (Genentech); Smita Salian-Mehta (Gilead); Isabel Figueroa Amenabar (Amgen); Laurence Fayadat-Dilman (Merck and Co); Minli Xie (Erasca); Snow Ge (Biobridge Pharma); Shichang Miao (Amgen)
Date:
2023-05-24
Time:
8:45-17:25 Pacific Time
Registration fee:
Regular attendees: $295; Academic/Students/Postdocs: $125; Major Sponsorship: $3000; Vendor Show: $695; On-site Registration:$500
Location:
Crowne Plaza, Foster City, CA (San Francisco Bay Area)
Major Sponsor:
Vendor show vendors registered to date:
(23)Abzena; Alturas Analytics; Biointron; BioTether Sciences; Charles River Labs; CHIRON Recombinant Proteins; Correlia Biosystems Inc; CP Lab Safety; Ellegaard BioResearch; Emery Pharma; Frontage Laboratories; Gator Bio; GBI Bio; Inotiv; IRBM; KCAS Bioanalytical & Biomarker Services; Meadowhawk Biolabs; Medicilon; MilliporeSigma; Novogene Corporation Inc.; Q2Lab Solutions; QPS, LLC; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2023-05-23
(it will close sooner if the seating cap is reached)
About the Topic
Commercial clinical pipeline of mAbs has vastly increased in recent years; the mAbs based therapeutics in development has been growing at an incredible pace. The investigational new drug application (IND) application is an important step to achieve in mAb based therapeutics, and understanding the requirements for a successful IND filing is utmost important to ensure fast and efficient development. While the principles and basics are similar across different modalities for an IND filing such as safety studies, there are important aspects that need to be considered for mAb based therapeutics. In this workshop, we will cover the best practices for a successful IND package of mAbs. Our highly experienced speakers will discuss the preclinical studies for mAb based therapeutics IND packages. This workshop will be suitable for novice drug developers and small molecule drug development experts who are interested in mAb therapeutic development.
Topics to be covered:
- Overview of preclinical development and IND filing requirements for antibody-based therapeutics
- Required preclinical studies for
Safety assessment
Pharmacology
Pharmacokinetics
CMC (Chemistry, Manufacturing, Control)
- Clinical development plans
- FDA’s perspective by an FDA reviewer
|
Time (PT)
|
Topic
|
Presenter
|
|
8:45-9:00 am
|
PBSS Welcome and Introduction
|
Snow Ge (BridgeBio Pharma)
|
|
9:00-9:20 am
|
1. Overview of preclinical development and IND filing requirements for antibody-based therapeutics
|
Ayse Meric Ovacik, PhD, Senior Principal Scientist, Genentech
|
|
9:20-9:50 am
|
2. Overview of antibody-based therapeutics: structure, generation, design, and optimization
|
Laurence Fayadat-Dilman, PhD, Executive Director, Discovery Biologics, Merck & Co, Inc.
|
|
9:50-10:25 am
|
3- Non-clinical pharmacology considerations for bi-specific antibodies
|
Keegan Cooke, BA, Principal Scientist
Oncology Research, Amgen
|
|
10:25-10:35 am
|
Major Sponsor’s Presentation
|
Mycenax Biotech Inc.
|
|
10:35-10:50am
|
Break Period & Vendor Show
|
-
|
|
10:50-11:45am
|
4- Pharmacokinetic/Pharmacodynamic and bioanalytical considerations for successful IND filings
|
Jay Tibbitts, DVM, PhD, Vice President Non-Clinical Development, Surrozen
|
|
11:45-12:35pm
|
Lunch
|
|
|
12:35-1:45pm
|
5- Preclinical toxicology points to consider for biotherapeutic IND submissions
|
Robert Caldwell, PhD, Senior Principal Research Scientist, Toxicology, AbbVie
|
|
1:45-2:45pm
|
6. IND-enabling CMC activities for therapeutic antibodies
|
Lilia Koriazova, PhD, Sr. Director, Biologics Pharmaceutical Sciences, R&D department, Erasca
|
|
2:45-2:55pm
|
Major Sponsor’s Presentation
|
Veloxity Labs
|
|
2:55-3:10pm
|
Break
|
-
|
|
3:10-3:45pm
|
7- Clinical Development Plan
|
Sara Glickstein Bar-Zeev, PhD, Senior Clinical Scientist, Genentech
|
|
3:45-4:15pm
|
8. Regulatory strategies and Interactions with FDA: Industry perspective & how to prepare for FDA meetings
|
Key Kang, MSc, Global Regulatory Leader and Group Director, Genentech Inc.
|
|
4:15-4:50pm
|
9- INDs for biologics: The regulatory perspective
|
Arianne Motter, PhD, DABT, Senior Toxicologist/CDER/OND/DPT-ID, U.S FDA
|
|
4:50-5:25pm
|
Panel Discussion
|
All Speakers
|
|
5:25-6:25pm
|
Happy Hour
|
Sponsor: Alturas Analytics
|
2023-06-20, [Free Online] Highlights of 2022 FDA Approvals
|
2023-08-17, [Free Online] The Science and Stories of Promising Biotech Startups
|
2023-09-08, [In-person] Distribution and Disposition Studies for Biotherapeutics for IND / NDA Filings: Multi-specifics, ADCs, Nucleotides, Peptide conjugates, and Protein Degraders
|
2023-09-21, [In-Person] Advances in Cancer Therapeutics
|
2023-10-06, [In-Person] Human PK and Dose Prediction for Small Molecules
|
2024-01-15, [In-Person] ADME/DMPK Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
|
Ads (in random order)
Submit a Text Ad
($250 for 2 months)
BioTether Sciences
Contract development, validation and regulated testing. Advanced cell engineering. Bioanalysis of cells, genes, and proteins.
|
Alturas Analytics, Inc.
Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
|
Hypha Discovery
Synthesis, purification & NMR characterization of phase I and II drug metabolites & API impurities at mg-g scale with COAs.
|
Origin Bioanalytical Laboratory, Inc.
Bioanalytical CRO specializing in LC-MS/MS method development, validation, non-GLP and GLP analysis to support PK/TK studies, with ocular expertise.
|
Allucent
Bringing innovation to Biopharma,w/ClinPharm Modeling & Simulation services to inform dose, design, modeling + development strategies.
|
|
|
Submit a Text Ad
|